ADAPY (Adaptimmune Therapeutics) Total Liabilities: $201.59 Mil (As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Adaptimmune Therapeutics Total Liabilities?

Adaptimmune Therapeutics ADAPY +5.80% Total Liabilities is $201.59 Mil as of Jun. 2025.

Adaptimmune Therapeutics's Total Liabilities for the quarter that ended in Jun. 2025 was $201.59 Mil.

Adaptimmune Therapeutics's quarterly Total Liabilities declined from Dec. 2024 ($234.11 Mil) to Mar. 2025 ($195.50 Mil) but then increased from Mar. 2025 ($195.50 Mil) to Jun. 2025 ($201.59 Mil).

Adaptimmune Therapeutics's annual Total Liabilities declined from Dec. 2022 ($247.04 Mil) to Dec. 2023 ($243.10 Mil) and declined from Dec. 2023 ($243.10 Mil) to Dec. 2024 ($234.11 Mil).

Adaptimmune Therapeutics Total Liabilities Historical Data

* Premium members only.

The historical data trend for Adaptimmune Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adaptimmune Therapeutics Total Liabilities Chart

Adaptimmune Therapeutics Annual Data
Trend Jun15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 109.92 263.59 247.04 243.10 234.11

Adaptimmune Therapeutics Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 225.43 237.45 234.11 195.50 201.59

Adaptimmune Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Adaptimmune Therapeutics's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=64.527+(69.5+4.272
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+95.815+0+0)
=234.11

Total Liabilities=Total Assets (A: Dec. 2024 )-Total Equity (A: Dec. 2024 )
=245.963-11.849
=234.11

Adaptimmune Therapeutics's Total Liabilities for the quarter that ended in Jun. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=51.513+(44.166+4.493
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+101.419+0+0)
=201.59

Total Liabilities=Total Assets (Q: Jun. 2025 )-Total Equity (Q: Jun. 2025 )
=130.633--70.958
=201.59

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $201.59 Mil mean?
Adaptimmune Therapeutics (ADAPY) has a Total Liabilities of $201.59 Mil as of Jun. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Adaptimmune Therapeutics and its competitors.
Is Adaptimmune Therapeutics' Total Liabilities too high?
Adaptimmune Therapeutics' current Total Liabilities is $201.59 Mil.
How does Adaptimmune Therapeutics' Total Liabilities compare to BCLI and APRE?
Adaptimmune Therapeutics' Total Liabilities of $201.59 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Adaptimmune Therapeutics and its competitors. Adaptimmune Therapeutics's current Total Liabilities is $201.59 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adaptimmune Therapeutics stock overvalued right now?
Adaptimmune Therapeutics (ADAPY) has a current Total Liabilities of $201.59 Mil. The current Total Liabilities is $201.59 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Adaptimmune Therapeutics (ADAPY), the current Total Liabilities is $201.59 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Adaptimmune Therapeutics Business Description

Other Exchanges 473A:Germany
Address 99 Park Drive, Milton Park, The Innovation Centre, Abingdon, Oxfordshire, GBR, OX14 4RY
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its product pipelines include ADP-600 [PRAME] and ADP-520 [CD70].